Screening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation Statement

DESCRIPTION Update of the 2008 U.S. Preventive Services Task Force (USPSTF) recommendation statement on screening for prostate cancer. METHODS The USPSTF reviewed new evidence on the benefits and harms of prostate-specific antigen (PSA)-based screening for prostate cancer, as well as the benefits and harms of treatment of localized prostate cancer. RECOMMENDATION The USPSTF recommends against PSA-based screening for prostate cancer (grade D recommendation).This recommendation applies to men in the general U.S. population, regardless of age. This recommendation does not include the use of the PSA test for surveillance after diagnosis or treatment of prostate cancer; the use of the PSA test for this indication is outside the scope of the USPSTF.

• Publication year

  2012

• Venue

  Annals of Internal Medicine

• Publication date

  2012-07-17

• Fields of study

  Medicine

• Identifiers
  DOI 10.7326/0003-4819-157-2-201207170-00459PMID 22801674
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up.

  2012cited by this paper
• The Prostate Cancer Intervention Versus Observation Trial: VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy with watchful waiting for men with clinically localized prostate cancer.

  2012cited by this paper
• Prostate-cancer mortality at 11 years of follow-up.

  2012cited by this paper
• New data on prostate-cancer mortality after PSA screening.

  2012cited by this paper
• Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study

  2012cited by this paper
• The watchman.

  2012cited by this paper
• Comorbidity and mortality results from a randomized prostate cancer screening trial.

  2011cited by this paper
• Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials.

  2011cited by this paper
• Do the data support the comorbidity hypothesis for the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial results?

  2011cited by this paper
• Treatments for Localized Prostate Cancer: Systematic Review to Update the 2002 U.S. Preventive Services Task Force Recommendation

  2011cited by this paper
• An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection.

  2011cited by this paper
• Complications after prostate biopsy: data from SEER-Medicare.

  2011cited by this paper
• Screening for Prostate Cancer: A Review of the Evidence for the U.S. Preventive Services Task Force

  2011cited by this paper
• Randomised prostate cancer screening trial: 20 year follow-up

  2011cited by this paper
• Calcium and magnesium infusions for prevention of oxaliplatin-induced peripheral neuropathy.

  2011cited by this paper
• The risks and benefits of 5α-reductase inhibitors for prostate-cancer prevention.

  2011cited by this paper
• Long-term quality-of-life outcomes after radical prostatectomy or watchful waiting: the Scandinavian Prostate Cancer Group-4 randomised trial.

  2011cited by this paper
• The effect of study arm on prostate cancer treatment in the large screening trial ERSPC

  2010cited by this paper
• Comparative Effectiveness of Minimally Invasive vs Open Radical Prostatectomy

  2010cited by this paper
• False-positive screening results in the Finnish prostate cancer screening trial

  2010cited by this paper
• Time trends and local variation in primary treatment of localized prostate cancer.

  2010cited by this paper
• American Cancer Society Guideline for the Early Detection of Prostate Cancer: Update 2010

  2010cited by this paper
• The benefits and harms of mammography screening: understanding the trade-offs.

  2010cited by this paper
• Overdiagnosis in cancer.

  2010cited by this paper
• Mortality results from the Göteborg randomised population-based prostate-cancer screening trial.

  2010cited by this paper
• Population‐based prostate‐specific antigen testing in the UK leads to a stage migration of prostate cancer

  2009cited by this paper
• The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer.

  2009cited by this paper
• Screening and prostate-cancer mortality in a randomized European study.

  2009cited by this paper
• Trials of prostate-cancer screening are not worthwhile.

  2009cited by this paper
• Outcomes of localized prostate cancer following conservative management.

  2009cited by this paper
• Comparative effectiveness of minimally invasive vs open radical prostatectomy.

  2009cited by this paper
• Health-related quality of life 10 years after external beam radiotherapy or watchful waiting in patients with localized prostate cancer

  2009cited by this paper
• Prostate specific antigen best practice statement: 2009 update.

  2009cited by this paper
• Mortality results from a randomized prostate-cancer screening trial.

  2009cited by this paper
• Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005.

  2009cited by this paper
• Cumulative Incidence of False-Positive Results in Repeated, Multimodal Cancer Screening

  2009cited by this paper
• 15-year followup of a population based prostate cancer screening study.

  2009cited by this paper
• The ProtecT trial: evaluating the effectiveness of treatments for clinically localised prostate cancer

  2009cited by this paper
• Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement.

  2008cited by this paper
• Survival following primary androgen deprivation therapy among men with localized prostate cancer.

  2008cited by this paper
• Screening for prostate cancer in U.S. men ACPM position statement on preventive practice.

  2008cited by this paper
• Systematic Review: Comparative Effectiveness and Harms of Treatments for Clinically Localized Prostate Cancer

  2008cited by this paper
• Benefits and Harms of Prostate-Specific Antigen Screening for Prostate Cancer: An Evidence Update for the U.S. Preventive Services Task Force

  2008cited by this paper
• Associations of lower urinary tract symptoms with prostate‐specific antigen levels, and screen‐detected localized and advanced prostate cancer: a case‐control study nested within the UK population‐based ProtecT (Prostate testing for cancer and Treatment) study

  2008cited by this paper
• Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial.

  2008cited by this paper
• Interval cancers in prostate cancer screening: comparing 2- and 4-year screening intervals in the European Randomized Study of Screening for Prostate Cancer, Gothenburg and Rotterdam.

  2007cited by this paper
• Prostate cancer screening decreases the absolute risk of being diagnosed with advanced prostate cancer--results from a prospective, population-based randomized controlled trial.

  2007cited by this paper
• Prostate cancer epidemiology.

  2006cited by this paper
• The Efficacy and Safety of Multivitamin and Mineral Supplement Use To Prevent Cancer and Chronic Disease in Adults: A Systematic Review for a National Institutes of Health State-of-the-Science Conference

  2006cited by this paper
• The impact of a suspicious prostate biopsy on patients’ psychological, socio-behavioral, and medical care outcomes

  2006cited by this paper
• Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower.

  2005cited by this paper
• Radical prostatectomy versus watchful waiting in early prostate cancer.

  2005cited by this paper
• 20-year outcomes following conservative management of clinically localized prostate cancer.

  2005cited by this paper
• Prostate-specific antigen levels in the United States: implications of various definitions for abnormal.

  2005cited by this paper
• Radical prostatectomy versus watchful waiting in early prostate cancer.

  2005cited by this paper
• Changing patterns in competing causes of death in men with prostate cancer: a population based study.

  2004cited by this paper
• Psychological effects of a suspicious prostate cancer screening test followed by a benign biopsy result.

  2004cited by this paper
• Screening decreases prostate cancer mortality: 11‐year follow‐up of the 1988 Quebec prospective randomized controlled trial

  2004cited by this paper
• Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter.

  2004cited by this paper
• The influence of finasteride on the development of prostate cancer.

  2003cited by this paper
• Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer.

  2003cited by this paper
• Prostate cancer epidemiology.

  2003cited by this paper
• Complication rates and risk factors of 5802 transrectal ultrasound-guided sextant biopsies of the prostate within a population-based screening program.

  2002cited by this paper
• Causes of death in elderly prostate cancer patients and in a comparison nonprostate cancer cohort.

  2000cited by this paper
• American Cancer Society guidelines for the early detection of cancer

  2000cited by this paper
• A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer.

  1995cited by this paper
• Radical prostatectomy versus expectant treatment for early carcinoma of the prostate. Twenty-three year follow-up of a prospective randomized study.

  1995cited by this paper
• The prostate cancer intervention versus observation trial

  1994cited by this paper
• The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients.

  1993cited by this paper
• Screening for prostate cancer

  1993cited by this paper

• The evolving role of PSA in prostate cancer screening: revisiting the evidence in the era of personalized medicine

  2026cites this paper
• Cancer statistics, 2026

  2026cites this paper
• Cancer screening and early detection

  2026cites this paper
• Multilevel associations between prostate cancer testing and socioeconomic position: a population-based register study from Stockholm, Sweden.

  2026cites this paper
• Cancer incidence and mortality trends among older adults.

  2026cites this paper
• Assessing digital rectal examination and prostate-specific antigen knowledge: a study of Syrian medical students’ knowledge for prostate cancer screening

  2026cites this paper
• RNA-Seq Uncovers Association of Endocrine-Disrupting Chemicals with Hub Genes and Transcription Factors in Aggressive Prostate Cancer

  2025cites this paper
• Temporal trends of prostate cancer diagnostics in Australia: Has the introduction of a magnetic resonance imaging prostate subsidy fulfilled its cost-saving promises?

  2025cites this paper
• Gleason Grade Group 3 Represents a Spectrum of Disease: Results from a Large Institutional Cohort.

  2025cites this paper
• PSAzing up patient care: a quality improvement project for informed cancer screening

  2025cites this paper
• Overdiagnosis and Overtreatment: Boon or Bane?

  2025cites this paper
• Burden of prostate cancer in China during 1990–2021 and the projections through 2050

  2025cites this paper
• Trends in stage-specific prostate cancer incidence by neighborhood socioeconomic status

  2025cites this paper
• Factors associated with prostate cancer screening among Hispanic men: Results from the Hispanic Community Health Study/Study of Latinos

  2025cites this paper
• Cancer statistics, 2025

  2025cites this paper
• Advances in Current Treatment Paradigms for Metastatic Hormone-Sensitive Prostate Cancer

  2025cites this paper
• Divergent Trends in PSA Screening Prior to Testosterone Therapy in Younger vs. Older Men Amidst Shifting Guidelines.

  2025cites this paper
• Prostate Cancer Mortality Trend in Montenegro 1990–2018

  2025cites this paper
• Long-term Cancer Control Outcomes After Robot-assisted Radical Prostatectomy in Pathologically Non-organ-confined High-risk Prostate Cancer: 20-year Report from a Single Tertiary Referral Center.

  2025cites this paper
• MRI Fusion Cryoablation: Is There an Outcome Difference Between Anterior and Posterior Lesions?

  2025cites this paper
• Do We Still Need Randomized Controlled Trials to Support Use of New Methods of Breast Cancer Screening?

  2025cites this paper
• Prostate Cancer, Version 3.2026, NCCN Clinical Practice Guidelines In Oncology.

  2025cites this paper
• Using Machine Learning to Create Prognostic Systems for Primary Prostate Cancer

  2025cites this paper
• Mortality and Additional Treatment Rates in Pathologically High‐Risk Prostate Cancer With Prostate‐Specific Antigen Persistence at Robot‐Assisted Radical Prostatectomy: Long‐Term Report From Single Tertiary Referral Center

  2025cites this paper
• Challenges of cancer registration and epidemiology in Italy.

  2025cites this paper
• Epidemiology of Early Onset Prostate Cancer: Global Patterns, Risk Factors, and Projections Through 2040

  2025cites this paper
• Prostate cancer clinicopathological presentation in South-East Africa during the 2010 decade

  2025cites this paper
• Time to de-implementation of low-value cancer screening practices: a narrative review

  2025cites this paper
• Comparative Effectiveness Analysis of Different Prostate Cancer Screening Strategies: A Systematic Review and Meta-Analysis

  2025cites this paper
• Prostate cancer in Türkiye: Trend analysis of incidence and mortality rates.

  2025cites this paper
• Trends bei der chirurgischen Überbehandlung von Prostatakrebs

  2025cites this paper
• Sustained PSA screening is associated with downstaging and improved survival in prostate cancer: a 12-year Korean cohort study

  2025cites this paper
• Nanomaterial-Mediated Electrochemical and Optical Biosensors and Their Application in Tumour Marker Detection

  2025cites this paper
• From blue November to broader diagnosis: The Youden index to evaluate the performance of any diagnostic tests

  2025cites this paper
• Trends and Disparities in Prostate Cancer Mortality in the United States (1999-2020).

  2025cites this paper
• Prostate Cancer Screening: Evolution, Challenges, and Future Directions.

  2025cites this paper
• IGFBP3-SphK1/S1P Signaling Axis Drives Enzalutamide Resistance in Advanced Prostate Cancer.

  2025cites this paper
• An Evidenced Based Review and Common-Sense Approach to Prostate Cancer Screening for Primary Care Physicians, in an Era of Conflicting Guideline Recommendations and Debate

  2025cites this paper
• Global viewpoints: evolving epidemiology and treatment patterns of prostate cancer in Asia

  2025cites this paper
• Measurement of Prostate Specific Antigen Testing Among Primary Care Patients in the United States, 2010–2019

  2025cites this paper
• Circulating microRNAs as biomarker in prostate cancer and their significance in the differentiation of benign and malignant conditions of the prostate

  2025cites this paper
• Prostate cancer statistics, 2025

  2025cites this paper
• Canadian Prostate Cancer Trends in the Context of PSA Screening Guideline Changes

  2025cites this paper
• Can the systemic immune-inflammation index be used to differentiate benign and malignant pathologies before transrectal ultrasound-guided prostate biopsy?

  2025cites this paper
• Prostate Cancer 2025.

  2025cites this paper
• Addressing barriers to care for African American men facing prostate cancer: a scoping review of navigation programs

  2025cites this paper
• Learning from prostate cancer statistics

  2025cites this paper
• PROSTest, a Multigene Liquid Biopsy Signature, Effectively Stratifies Patients With High PSA for Prostate Biopsy

  2025cites this paper
• A case of high-grade prostate cancer with low PSA levels

  2025cites this paper
• Transperineal MRI-US Fusion-Guided Biopsy with Systematic Sampling for Prostate Cancer: Diagnostic Accuracy and Clinical Implications Across PI-RADS

  2025cites this paper
• Evolving paradigms in prostate cancer screening: a decade of bibliometric insights and technological advancements

  2025cites this paper
• Cancer statistics for African American and Black people, 2025

  2025cites this paper
• Reduced prostate cancer screening has a negative impact on stage migration: the Australian experience

  2025cites this paper
• Global burden of prostate cancer: age-period-cohort analysis from 1990 to 2021 and projections until 2040

  2025cites this paper
• Trends in Surgical Overtreatment of Prostate Cancer.

  2025cites this paper
• Sialic Acids: Sweet Modulators Fueling Cancer Cells and Domesticating the Tumor Microenvironment.

  2025cites this paper
• The potential of plasma-derived medium-sized extracellular vesicles as a biopsy alternative for active surveillance decisions in prostate Cancer.

  2025cites this paper
• Survival Outcomes for Rural Patients With Advanced Prostate Cancer: A SEER Investigation

  2024cites this paper
• Over 48,000 baseline prostate-specific antigen measurements in young men: a 16-year time-analysis

  2024cites this paper
• Prostate magnetic resonance imaging utilization and its relationship with advanced prostate cancer detection.

  2024cites this paper
• Navigation-Based Telehealth Informed Decision-Making for Prostate Cancer Screening in Black Men

  2024cites this paper
• Prostate cancer temporal and regional trends in Brazil

  2024cites this paper
• Metastatic onset of prostate carcinoma: A clinical and pathological challenge.

  2024cites this paper
• Access to Prostate-Specific Antigen Testing and Mortality Among Men With Prostate Cancer

  2024cites this paper
• Receipt of Prostate-Specific Antigen Test in Medicaid Beneficiaries With and Without HIV in 2001–2015 in 14 States

  2024cites this paper
• Incidence of prostate cancer in Medicaid beneficiaries with and without HIV in 2001–2015 in 14 states

  2024cites this paper
• The present and future of prostate cancer. The importance of physical activity - a comprehensive review of the literature

  2024cites this paper
• Racial, ethnic, and socioeconomic disparities in rates of stage IV prostate cancer after USPSTF category “D” recommendation against prostate-specific antigen screening: a retrospective cohort study

  2024cites this paper
• The Influence of Disparities on Prostate Cancer at Diagnosis in the Charlotte Metropolitan Area

  2024cites this paper
• Reducing Prostate Cancer Disparities for Black Men.

  2024cites this paper
• Prostate cancer characteristics in Black septuagenarian men

  2024cites this paper
• Determinants of receipt of prostate cancer screening among men living with HIV enrolled in an urban HIV Clinic in the United States over the period of 2000-2020.

  2024cites this paper
• Development and validation of an imageless machine‐learning algorithm for the initial screening of prostate cancer

  2024cites this paper
• The association of patient and disease characteristics with the overtreatment of low-risk prostate cancer from 2010 to 2016

  2024cites this paper
• Actualización en detección precoz del cáncer de próstata

  2024cites this paper
• Increased α2,3‐sialyl N‐glycosylated prostate‐specific membrane antigen (PSMA) in post‐DRE urine is associated with high grade group prostate cancer

  2024cites this paper
• The effect of CLOSER-computer-based exercise program in older adults with a history of falls: A pilot study

  2024cites this paper
• Clinical performance and utility: A microsimulation model to inform the design of screening trials for a multi-cancer early detection test

  2024cites this paper
• Ex Vivo Fluorescence Confocal Microscopy of MRI-Guided Targeted Prostate Biopsies for Rapid Detection of Clinically Significant Carcinomas—A Feasibility Study

  2024cites this paper
• What is cancer? A focus on Grade Group 1 prostate cancer

  2024cites this paper
• Impacts on functional and oncological outcomes of Robotic-assisted Radical Prostatectomy 10 years after the US Preventive Service Taskforce recommendations against PSA screening

  2024cites this paper
• Cancer statistics, 2024

  2024cites this paper
• Machine Learning as a Tool for Early Detection: A Focus on Late-Stage Colorectal Cancer across Socioeconomic Spectrums

  2024cites this paper
• Prostate cancer biomarkers

  2024cites this paper
• The complex interplay of modifiable risk factors affecting prostate cancer disparities in African American men

  2024cites this paper
• Urinary fatty acid biomarkers for prostate cancer detection

  2024cites this paper
• Ultrasensitive prostate cancer marker PCA3 detection with impedimetric biosensor based on specific label-free aptamers

  2024cites this paper
• Tumor upgrading among very favorable intermediate-risk prostate cancer patients treated with robot-assisted radical prostatectomy: how can it impact the clinical course?

  2024cites this paper
• Prostate-Specific Antigen Screening in Smokers: A Comprehensive Analysis Using a National Behavioral Survey

  2024cites this paper
• Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

  2024cites this paper
• A Pragmatic Approach to Prostate Cancer Screening.

  2024cites this paper
• Spatial-temporal Bayesian accelerated failure time models for survival endpoints with applications to prostate cancer registry data

  2024cites this paper
• A Ten Year Experience of Men’s Health Events in a Socioeconomically Diverse City in the United States – Lessons Learned

  2024cites this paper
• Can weight-adjusted waist circumference index become a single anthropometric predictor of prostate-specific antigen concentration? A National Health and Nutrition Examination Survey analysis (2003–2010)

  2024cites this paper
• Aligning Cancer Research Priorities in Europe with Recommendations for Conquering Cancer: A Comprehensive Analysis

  2024cites this paper
• Trends in the incidence and survival of cancer in individuals aged 55 years and older in the United States, 1975–2019

  2024cites this paper
• Lifetime Health and Economic Outcomes of Biparametric Magnetic Resonance Imaging as First-Line Screening for Prostate Cancer

  2024cites this paper
• The Cost-Effectiveness of Prostate Cancer Screening That Incorporates Magnetic Resonance Imaging

  2024cites this paper
• MR Molecular Imaging of Extradomain-B Fibronectin for Assessing Progression and Therapy Resistance of Prostate Cancer

  2024cites this paper
• Mortality reduction and cumulative excess incidence (CEI) in the prostate-specific antigen (PSA) screening era

  2024cites this paper